Split-Face Trial Comparing PDRN vs HA for Rolling Acne Scars
Summary
A split-face randomized controlled clinical trial (NCT07547956) has been registered to evaluate the efficacy and safety of Polydeoxyribonucleotide (PDRN) injection versus non-cross linked Hyaluronic acid (HA) injection, both combined with subcision, for treating rolling acne scars. Each participant receives both treatments on opposite sides of the face to enable direct comparison. The study will assess clinical outcomes and improvement in scar appearance between the two injectable agents.
“In this split-face clinical trial, each participant will receive subcision on both sides of the face.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
The document registers a new randomized controlled clinical trial on ClinicalTrials.gov comparing two injectable agents for acne scar treatment. The trial employs a split-face design where rolling acne scar patients receive subcision with Polydeoxyribonucleotide (PDRN) on one side of the face and subcision with non-cross linked Hyaluronic acid (HA) on the other. Both treatments will be assessed for clinical outcomes and scar appearance improvement.
Healthcare providers and clinical investigators conducting aesthetic dermatology research should note this trial as a source of emerging evidence on injectable adjuncts to subcision for acne scar management. The comparison between PDRN and HA may inform future treatment protocols and clinical decision-making in dermatology and plastic surgery settings.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment : A Split Face Randomized Controlled Clinical Trial
N/A NCT07547956 Kind: NA Apr 23, 2026
Abstract
The aim of this study is to evaluate and compare the efficacy and safety of two different injectable agents combined with subcision for treating rolling acne scars. In this split-face clinical trial, each participant will receive subcision on both sides of the face. One side will then be treated with an injection of Polydeoxyribonucleotide (PDRN), while the other side will receive an injection of non-cross linked Hyaluronic acid (HA). The clinical outcomes and improvement in scar appearance will be assessed and compared between both treatments
Conditions: Rolling Acne Scars
Interventions: subcision with PDRN vs HA injection
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.